Compare Amgen, Inc. (AMGN) vs Innodata Inc (INOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Innodata Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Innodata Inc trades at $67.3 (market cap $2.21B). The key difference: Amgen, Inc. is far larger — about 88.7× Innodata Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| AMGN | INOD | |
|---|---|---|
Market Cap | $196.12B | $2.21B |
Sector | Health | Technology |
52-Week High | $388.16 | $121.50 |
52-Week Low | $271.18 | $34.45 |
Enterprise Value | $241.41B | $2.10B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
INOD trades at $67.80, down 1.99% amid bearish technical signals despite strong fundamental performance. The stock shows robust revenue growth with 2025 revenue of $251.66M and net income of $32.18M, supported by consistent earnings beats. Analyst consensus remains bullish with a $130 price target, though recent insider selling and technical weakness create near-term pressure.
Outlook remains positive given AI-driven growth potential and strong profitability metrics, but investors face volatility risks from high valuation multiples and competitive pressures in the AI data services space. The stock's current pullback presents a potential entry point for long-term investors believing in the AI growth story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
